000148182 001__ 148182
000148182 005__ 20250114175434.0
000148182 0247_ $$2doi$$a10.1016/j.arteri.2020.12.006
000148182 0248_ $$2sideral$$a126621
000148182 037__ $$aART-2021-126621
000148182 041__ $$aspa
000148182 100__ $$aMarco-Benedí V.
000148182 245__ $$aCarga de enfermedad. Cálculo del riesgo cardiovascular y objetivos terapéuticos
000148182 260__ $$c2021
000148182 5060_ $$aAccess copy available to the general public$$fUnrestricted
000148182 5203_ $$aTherapeutic intervention should be determined by the risk of developing atheromatous cardiovascular disease (CVD). The higher the risk, the more intense the action should be. This is the reason for the stratification of patient risk. In primary prevention, the two main guidelines used, the American Heart Association and the American College of Cardiology (ACC/AHA) use the Pooled cohort equations (PCE) and the guidelines of the European societies use the SCORE tables. The PCE calculates the risk of fatal and non-fatal CVD, and the SCORE calculates risk of fatal CVD only. In young people, it is useful to consider the lifetime risk calculation. The Spanish Society of Arteriosclerosis (SEA) recommends the SCORE system in Spain. SCORE and PCE calculate the risk for people up to 70 and 75 years of age. Prediction and potentials are available for 80 years of age and above, with the data available being much more scarce. Risk stratification in secondary prevention may be useful to identify the subgroup of patients who may benefit from more intensive treatment. Imaging tests, especially coronary calcium scans and vascular ultrasound, can help to better the profile risk. European guidelines identify LDL cholesterol as a therapeutic target. They recommend initiating treatment with statins, and increasing dose and potency until targets are achieved, and then to treatment with potent statins at a maximum tolerated dose, and ezetimibe if targets are not achieved. As a third step, PCSK9 inhibitors are indicated. They set very ambitious targets, as low as 40 mg/dL in those subjects with recurrences before two years of CVD despite high-intensity statin therapy, and below 55 mg/dL for all very high-risk subjects. © 2021 Sociedad Española de Arteriosclerosis
000148182 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000148182 592__ $$a0.325$$b2021
000148182 593__ $$aPharmacology (medical)$$c2021$$dQ3
000148182 593__ $$aCardiology and Cardiovascular Medicine$$c2021$$dQ3
000148182 594__ $$a2.1$$b2021
000148182 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000148182 700__ $$0(orcid)0000-0001-9142-0737$$aJarauta Simón E.$$uUniversidad de Zaragoza
000148182 700__ $$0(orcid)0000-0003-3963-0846$$aLaclaustra Gimeno M.$$uUniversidad de Zaragoza
000148182 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira Murillo F.$$uUniversidad de Zaragoza
000148182 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000148182 773__ $$g33 (2021), 10-17$$pClín. investig. arterioscler.$$tClinica e Investigacion en Arteriosclerosis$$x0214-9168
000148182 8564_ $$s610252$$uhttps://zaguan.unizar.es/record/148182/files/texto_completo.pdf$$yVersión publicada
000148182 8564_ $$s2057861$$uhttps://zaguan.unizar.es/record/148182/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000148182 909CO $$ooai:zaguan.unizar.es:148182$$particulos$$pdriver
000148182 951__ $$a2025-01-14-15:49:00
000148182 980__ $$aARTICLE